Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease

Summary by PR Newswire
/PRNewswire/ -- BrainXell Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the...

7 Articles

Queen Creek TribuneQueen Creek Tribune
+6 Reposted by 6 other sources
Center

BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease

SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- BrainXell Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the Cell Symposia | Gene and Cell-Based Therapies: Progress in Clinical Translation and…

·Queen Creek, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Monday, November 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Parkinson's Disease icon

Parkinson's Disease

San Diego icon

San Diego

News
For You
SearchBlindspotLocal